Nodality and Celgene Form Drug Development Collaboration
South San Francisco, CA, July 16, 2010Nodality, Inc., a biotechnology company that applies proprietary single cell based technology in the development of personalized medicine tests and therapies in cancer and autoimmune disease, today announced a collaboration with Celgene Corporation to support early stage clinical drug development.
Under the terms of the agreement, Celgene will fund research conducted by Nodality using Single Cell Network Profiling (SCNP) technology to facilitate more efficient therapeutics development.
“This agreement underscores the potential benefits for SCNP as a drug development tool in early phase clinical research,” commented David R. Parkinson, M.D., President and Chief Executive Officer of Nodality, Inc. “The collaboration with Celgene represents how the application of SCNP in drug development can complement existing methods with the goal of more efficient drug development that ultimately results in better linkage of individual patients with appropriate therapies.”
Financial terms of the agreement were not disclosed.
About NodalityNodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments.
About Single Cell Network ProfilingSingle Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signalling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.